Skip to main content

Table 2 Fatty acid analysis of PC-3 cells that were supplemented with various fatty acids at the end of 48 hours of supplementation of various fatty acids

From: Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro

Fatty acids in PC-3

Composition percentage (%)

 

Linolelaidic acid

Linoleic acid

γ-linolenic acid

Arachidonic acid

α-linolenic acid

EPA

DHA

Control

2.25 ± 0.01

0.14 ± 0.01

0.88 ± 0.03

1.22 ± 0.03

0.12 ± 0..01

N.D

0.71 ± 0.03

LA(50 μM)

0.05 ± 0.01***

0.80 ± 0.10**

0.40 ± 0.08*

1.25 ± 0.19

0.09 ± 0.02

0.89 ± 0.11**

0.58 ± 0.06

LA(150 μM)

6.05 ± 0.08**

1.92 ± 0.38***

0.42 ± 0.14*

0.88 ± 0.12*

5.58 ± 0.39***

2.48 ± 0.34***

3.02 ± 0.26**

GLA(25 μM)

1.62 ± 0.18*

0.19 ± 0.08

0.97 ± 0.08

15.29 ± 2.73***

1.83 ± 0.37**

N.D

0.50 ± 0.12

GLA(50 μM)

1.56 ± 0.10*

0.20 ± 0.02

1.08 ± 0.28

22.24 ± 0.31***

4.87 ± 0.32***

N.D

0.53 ± 0.01

GLA(75 μM)

1.11 ± 0.05**

0.16 ± 0.06

0.76 ± 0.00

29.28 ± 0.52***

10.98 ± 0.45***

N.D

0.35 ± 0.01*

AA(50 μM)

1.94 ± 0.04

0.08 ± 0.01**

0.09 ± 0.01***

14.28 ± 0.44***

0.08 ± 0.01

0.37 ± 0.01*

0.69 ± 0.09

AA(100 μM)

1.88 ± 0.04

0.08 ± 0.01**

0.08 ± 0.01***

22.20 ± 0.63***

0.07 ± 0.01

0.46 ± 0.01*

0.62 ± 0.09

ALA(50 μM)

0.60 ± 0.08***

0.45 ± 0.08*

0.72 ± 0.24

1.49 ± 0.35*

0.51 ± 0.13*

1.98 ± 0.42**

4.83 ± 0.68**

ALA(150 μM)

0.66 ± 0.27***

1.32 ± 0.20***

0.82 ± 0.33

1.13 ± 0.13

2.13 ± 0.18**

1.64 ± 0.40**

2.50 ± 0.35**

EPA(50 μM)

2.46 ± 0.65

0.26 ± 0.05*

1.35 ± 0.12*

1.17 ± 0.31

0.11 ± 0.005

2.78 ± 0.03***

9.56 ± 0.38***

EPA(100 μM)

1.79 ± 0.13*

0.24 ± 0.03*

1.16 ± 0.02*

1.37 ± 0.05*

0.14 ± 0.03

5.64 ± 1.80***

14.11 ± 2.57***

DHA(50 μM)

1.98 ± 0.10*

0.24 ± 0.02*

1.08 ± 0.03*

1.30 ± 0.02

N.D

N.D

11.17 ± 1.08***

DHA 100 μM

1.88 ± 0.04*

0.21 ± 0.02*

0.99 ± 0.09

1.32 ± 0.07

0.11 ± 0.02

0.11 ± 0.01*

19.08 ± 0.06***

  1. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control.